Children with metabolically healthy obesity have a worse metabolic profile compared to normal-weight peers: a cross-sectional study.


Journal

Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444

Informations de publication

Date de publication:
09 2021
Historique:
received: 19 01 2021
accepted: 10 05 2021
pubmed: 24 5 2021
medline: 21 9 2021
entrez: 23 5 2021
Statut: ppublish

Résumé

A phenotype of metabolically healthy obesity (MHO) has been described in youth with obesity, but data are still scarce in this age group. The aim of the current study was to describe and compare clinical and laboratory parameters related to obesity among three different groups of youth, namely youth with normal weight (NW), with MHO, and with metabolically unhealthy obesity (MUO). One hundred and three youngsters with obesity were divided according to 2018 consensus-based criteria into those with MHO [n = 49, age (±SD): 10.9 ± 2.9 years] and those with MUO [n = 54, 11.5 ± 2.7 years] and were compared to age-, sex- and Tanner-matched NW [n = 69, 11.3 ± 2.9 years]. Several obesity-related parameters were investigated for all three groups of children. Comparisons were made by analysis of variance (ANOVA) followed by the Fisher's PLSD test. Youth with MHO had lower systolic (p < 0.001) and diastolic (p < 0.01) blood pressure z-score and triglycerides (p < 0.01), but higher HDL-C (p < 0.001), total cholesterol (p < 0.05), and apo-A1 (p < 0.05) compared to those with MUO. Compared to controls, both children with MHO and MUO showed higher fasting insulin (p < 0.05), HOMA-IR (p < 0.05), and QUICKI (p < 0.001). Similarly, both groups had higher hsCRP, fibrinogen, uric acid, and leptin compared to controls (for all, p < 0.001), while their adiponectin was lower (p < 0.05). Visfatin was higher in children with MUO compared to controls (p < 0.01), and it showed a trend to be lower in children with MHO compared to those with MUO (p = 0.1). This study provides evidence that children identified as having MHO by the consensus-based criteria had better metabolic profiles than youth with MUO, but worse than NW. Further research is needed in pediatric populations both regarding MHO criteria and the nature of the MHO phenotype per se.

Identifiants

pubmed: 34023981
doi: 10.1007/s12020-021-02762-6
pii: 10.1007/s12020-021-02762-6
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

580-587

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

J. Bentham, M. Di Cesare, V. Bilano, et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 390: 2627–2642 (2017)
R. Lakshman, C.E. Elks, K.K. Ong, Childhood obesity. Circulation 126, 1770–1779 (2012)
pubmed: 23027812 pmcid: 3785130 doi: 10.1161/CIRCULATIONAHA.111.047738
S.J. Olshansky, D.J. Passaro, R.C. Hershow et al. A potential decline in life expectancy in the united states in the 21st century. N. Engl. J. Med. 352, 1138–1145 (2005)
pubmed: 15784668 doi: 10.1056/NEJMsr043743 pmcid: 15784668
A. Tsatsoulis, S.A. Paschou, Metabolically healthy obesity: criteria, epidemiology, controversies, and consequences. Curr. Obes. Rep. 9, 109–120 (2020)
pubmed: 32301039 doi: 10.1007/s13679-020-00375-0 pmcid: 32301039
H. Lin, L. Zhang, R. Zheng et al. The prevalence, metabolic risk and effects of lifestyle intervention for metabolically healthy obesity: a systematic review and meta-analysis. Medicine 96, e8838 (2017)
pubmed: 29381992 pmcid: 5708991 doi: 10.1097/MD.0000000000008838
R.L. Prince, J.L. Kuk, K.A. Ambler et al. Predictors of metabolically healthy obesity in children. Diabetes Care 37, 1462–1468 (2014)
pubmed: 24574347 doi: 10.2337/dc13-1697 pmcid: 24574347
D.Y. Yoon, Y.A. Lee, J. Lee et al. Prevalence and clinical characteristics of metabolically healthy obesity in Korean children and adolescents: data from the Korea National Health and Nutrition Examination Survey. J. Korean Med. Sci. 32, 1840–1847 (2017)
pubmed: 28960038 pmcid: 5639066 doi: 10.3346/jkms.2017.32.11.1840
R. Vukovic, T.J. Dos Santos, M. Ybarra et al. Children with metabolically healthy obesity: a review. Front. Endocrinol. 10, 865 (2019)
doi: 10.3389/fendo.2019.00865
R. Weiss, S.E. Taksali, S. Dufour et al. The “Obese insulin-sensitive” adolescent: Importance of adiponectin and lipid partitioning. J. Clin. Endocrinol. Metab. 90, 3731–3737 (2005)
pubmed: 15797955 doi: 10.1210/jc.2004-2305 pmcid: 15797955
R. Vukovic, T. Milenkovic, K. Mitrovic et al. Preserved insulin sensitivity predicts metabolically healthy obese phenotype in children and adolescents. Eur. J. Pediatr. 174, 1649–1655 (2015)
pubmed: 26141171 doi: 10.1007/s00431-015-2587-4 pmcid: 26141171
D. Weghuber, S. Zelzer, I. Stelzer et al. High risk vs “metabolically healthy” phenotype in juvenile obesity—neck subcutaneous adipose tissue and serum uric acid are clinically relevant. Exp. Clin. Endocrinol. Diabetes 121, 384–390 (2013)
pubmed: 23519645 doi: 10.1055/s-0033-1341440 pmcid: 23519645
L. Bervoets, G. Massa, Classification and clinical characterization of metabolically “healthy” obese children and adolescents. J. Pediatr. Endocrinol. Metab. 29, 553–560 (2016)
pubmed: 26910741 doi: 10.1515/jpem-2015-0395 pmcid: 26910741
C. Cadenas-Sanchez, J.R. Ruiz, I. Labayen et al. Prevalence of metabolically healthy but overweight/obese phenotype and its association with sedentary time, physical activity, and fitness. J. Adolesc. Heal. 61, 107–114 (2017)
doi: 10.1016/j.jadohealth.2017.01.018
M.L. Evia-Viscarra, R. Guardado-Mendoza. Comparison between metabolically healthy obesity and metabolically unhealthy obesity by different definitions among Mexican children. J. Pediatr. Endocrinol. Metab. 33, 215–222 (2020)
pubmed: 31834862 doi: 10.1515/jpem-2019-0077 pmcid: 31834862
S. Damanhoury, A.S. Newton, M. Rashid et al. Defining metabolically healthy obesity in children: a scoping review. Obes. Rev. 19, 1476–1491 (2018)
pubmed: 30156016 doi: 10.1111/obr.12721 pmcid: 30156016
F. Magkos, Metabolically healthy obesity: what’s in a name? Am. J. Clin. Nutr. 110, 533–537 (2019)
pubmed: 31240297 doi: 10.1093/ajcn/nqz133 pmcid: 31240297
R. Caleyachetty, G.N. Thomas, K.A. Toulis et al. Metabolically healthy obese and incident cardiovascular disease events among 3.5 million men and women. J. Am. Coll. Cardiol. 70, 1429–1437 (2017)
pubmed: 28911506 doi: 10.1016/j.jacc.2017.07.763 pmcid: 28911506
M. Blüher, Obesity: the myth of innocent obesity. Nat. Rev. Endocrinol. 13, 691–692 (2017)
pubmed: 29118353 doi: 10.1038/nrendo.2017.146 pmcid: 29118353
K.D. Tambalis, D.B. Panagiotakos, G. Arnaoutis et al. Establishing cross-sectional curves for height, weight, body mass index and waist circumference for 4- to 18-year-old Greek children, using the Lambda Mu and Sigma (LMS) statistical method. Hippokratia 19, 239–248 (2015)
pubmed: 27418784 pmcid: 4938472
B. Falkner, S.R. Daniels. Summary of the fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Hypertension 44, 387–388 (2004)
pubmed: 15353515 doi: 10.1161/01.HYP.0000143545.54637.af
W.A. Marshall, J.M. Tanner, Variations in the pattern of pubertal changes in boys. Arch. Dis. Child 45, 13–23 (1970)
pubmed: 5440182 pmcid: 2020414 doi: 10.1136/adc.45.239.13
W.A. Marshall, J.M. Tanner, Variations in pattern of pubertal changes in girls. Arch. Dis. Child 44, 291–303 (1969)
pubmed: 5785179 pmcid: 2020314 doi: 10.1136/adc.44.235.291
D.R. Matthews, J.P. Hosker, A.S. Rudenski et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985)
doi: 10.1007/BF00280883 pubmed: 3899825
A. Katz, S.S. Nambi, K. Mather et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J. Clin. Endocrinol. Metab. 85, 2402–2410 (2000)
pubmed: 10902785 doi: 10.1210/jcem.85.7.6661 pmcid: 10902785
W.T. Friedewald, R.I. Levy, D.S. Fredrickson. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18, 499–502 (1972)
pubmed: 4337382 doi: 10.1093/clinchem/18.6.499 pmcid: 4337382
U. Lausten-Thomsen, M. Christiansen, C.E. Fonvig et al. Reference values for serum total adiponectin in healthy non-obese children and adolescents. Clin. Chim. Acta 450, 11–14 (2015)
pubmed: 26169157 doi: 10.1016/j.cca.2015.07.012 pmcid: 26169157
M.B. Horlick, M. Rosenbaum, M. Nicolson et al. Effect of puberty on the relationship between circulating leptin and body composition. J. Clin. Endocrinol. Metab. 85, 2509–2518 (2000)
pubmed: 10902802 pmcid: 10902802
D. Taşkesen, B. Kirel, T. Us. Serum visfatin levels, adiposity and glucose metabolism in obese adolescents. J. Clin. Res. Pediatr. Endocrinol. 4, 76–81 (2012)
pubmed: 22672864 pmcid: 3386777 doi: 10.4274/Jcrpe.547
U. Sack, U. Burkhardt, M. Borte et al. Age-dependent levels of select immunological mediators in sera of healthy children. Clin. Diagn. Lab. Immunol. 5, 28–32 (1998)
pubmed: 9455875 pmcid: 121386 doi: 10.1128/CDLI.5.1.28-32.1998
D. Altman, Sample size, in Practical Statistics for Medical Research (Chapman & Hall, London, 1994), pp. 456–60
G. O’Malley, N. Santoro, V. Northrup et al. High normal fasting glucose level in obese youth: a marker for insulin resistance and beta cell dysregulation. Diabetologia 53, 1199–1209 (2010)
pubmed: 20204321 doi: 10.1007/s00125-010-1693-0 pmcid: 20204321
E. Hagman, T. Reinehr, J. Kowalski et al. Impaired fasting glucose prevalence in two nationwide cohorts of obese children and adolescents. Int. J. Obes. 38, 40–45 (2014)
doi: 10.1038/ijo.2013.124
K.A. Christou, G.A. Christou, A. Karamoutsios et al. Metabolically healthy obesity is characterized by a proinflammatory phenotype of circulating monocyte subsets. Metab. Syndr. Relat. Disord. 17, 259–265 (2019)
pubmed: 30864887 doi: 10.1089/met.2018.0132 pmcid: 30864887
S. Genovesi, L. Antolini, A. Orlando, et al. Cardiovascular risk factors associated with the metabolically healthy obese (MHO) phenotype compared to the metabolically unhealthy obese (MUO) phenotype in children. Front. Endocrinol. (Lausanne) 11, 27–35 (2020)
doi: 10.3389/fendo.2020.00027
J. Fu, Y. Li, I.C. Esangbedo et al. Circulating osteonectin and adipokine profiles in relation to metabolically healthy obesity in Chinese children: Findings from BCAMS. J. Am. Heart Assoc. 7, e009169 (2018)
pubmed: 30571596 pmcid: 6405551
W. Ding, H. Cheng, F. Chen et al. Adipokines are associated with hypertension in metabolically healthy obese (MHO) children and adolescents: a prospective population-based cohort study. J. Epidemiol. 28, 19–26 (2018)
pubmed: 29093301 pmcid: 5742375 doi: 10.2188/jea.JE20160141
G. Labruna, F. Pasanisi, C. Nardelli, et al. High leptin/adiponectin ratio and serum triglycerides are associated with an at-risk phenotype in young severely obese patients. Obesity (Silver Spring) 19, 1492–1496 (2011)
doi: 10.1038/oby.2010.309
I. Aldhoon-Hainerová, H. Zamrazilová, M. Hill et al. Insulin sensitivity and its relation to hormones in adolescent boys and girls. Metabolism 67, 90–98 (2017)
pubmed: 28081782 doi: 10.1016/j.metabol.2016.10.005 pmcid: 28081782
M.B. Vos, S.H. Abrams, S.E. Barlow et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the North American society of pediatric gastroenterology, hepatology and nutrition (NASPGHAN). J. Pediatr. Gastroenterol. Nutr. 64, 319–334 (2017)
pubmed: 28107283 pmcid: 5413933 doi: 10.1097/MPG.0000000000001482
Y. Kim, Y. Chang, Y.K. Cho, et al. Metabolically healthy versus unhealthy obesity and risk of fibrosis progression in non-alcoholic fatty liver disease. Liver Int. 39, 1884–1894 (2019)
pubmed: 31226232 doi: 10.1111/liv.14184
P.K.C. Selvakumar, M.N. Kabbany, R. Lopez et al. Prevalence and risk factors of nonalcoholic fatty liver disease in metabolically healthy obese adolescents in the United States: an analysis of national health and nutrition examination survey data. J. Hepatol. 66, S587–S588 (2017)
A. Lonardo, A. Mantovani, S. Lugari et al. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Ann. Hepatol. 19, 359–366 (2020)
pubmed: 32349939 doi: 10.1016/j.aohep.2020.03.001
M. Blüher, Metabolically healthy obesity. Endocr. Rev. 41, 405–420 (2020)
pmcid: 7098708 doi: 10.1210/endrev/bnaa004 pubmed: 7098708
G. Farello, A. Antenucci, S. Stagi et al. Metabolically healthy and metabolically unhealthy obese children both have increased carotid intima-media thickness: a case control study. BMC Cardiovasc. Disord. 18, 140–146 (2018)
pubmed: 29973145 pmcid: 6032770 doi: 10.1186/s12872-018-0874-5
M. Zhao, A. López-Bermejo, C.A. Caserta et al. Metabolically healthy obesity and high carotid intima-media thickness in children and adolescents: international childhood vascular structure evaluation Consortium. Diabetes Care 42, 119–125 (2019)
pubmed: 30420475 doi: 10.2337/dc18-1536 pmcid: 30420475

Auteurs

Anastasios Serbis (A)

Child Health Department, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Greece. tasos_serbis@yahoo.com.

Vasilieios Giapros (V)

Child Health Department, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Greece.

Stavroula A Paschou (SA)

Division of Endocrinology, Diabetes and Metabolism, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Ekaterini Siomou (E)

Child Health Department, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH